Article
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Blood cancer journal - 18 Jun 2024
Kaur Amandeep, Rojek Alexandra E, Symes Emily, Nawas Mariam T, Patel Anand A, Patel Jay L, Sojitra Payal, Aqil Barina, Sukhanova Madina, McNerney Megan E, Wu Leo P, Akmatbekov Aibek, Segal Jeremy, Tjota Melissa Y, Gurbuxani Sandeep, Cheng Jason X, Yeon Su-Yeon, Ravisankar Harini V, Fitzpatrick Carrie, Lager Angela, Drazer Michael W, Saygin Caner, Wanjari Pankhuri, Katsonis Panagiotis, Lichtarge Olivier, Churpek Jane E, Ghosh Sharmila B, Patel Ami B, Menon Madhu P, Arber Daniel A, Wang Peng, Venkataraman Girish
Abstract excerpt
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of complete response to first-line therapy (CR1) and outcomes, we assembled a cohort of 242 individuals with TP53-mutated myeloid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.